Food and Drug Administration Commissioner Marty Makary has resigned, marking a significant leadership shakeup inside President Donald Trump’s second-term health team as the agency navigates ongoing uncertainty over regulatory priorities and internal operations.
Makary, a Johns Hopkins surgeon who gained national attention during pandemic-era health policy debates, was confirmed by the Senate in March 2025 after being appointed by Trump to lead the FDA.
At the time, his selection was viewed as part of a broader effort to reshape federal health agencies following years of political conflict over COVID-19-era mandates, vaccine policy, and public trust in health institutions, according to Trending Politics.
His tenure soon drew internal pushback over how the FDA should balance regulatory caution with faster approvals, particularly in politically sensitive areas of public health policy.
President Trump acknowledged Makary’s departure while speaking to reporters on Tuesday.
“Well, I don’t want to say, but Marty’s a great guy, he’s a friend of mine, he’s a wonderful man and he’s going to be off,” Trump said, according to The Hill. “He was having some difficulty.”
Another source of tension during Makary’s tenure involved abortion-related drug oversight, particularly scrutiny from advocacy groups over the FDA’s handling of mifepristone reviews and broader regulatory decisions tied to reproductive health policy.
According to Politico, Makary also faced pressure from multiple directions, including criticism from industry stakeholders and political advocates who argued the agency’s decision-making process had slowed amid internal restructuring.
Reports also pointed to staffing turnover and management disputes contributing to broader instability inside the FDA.
The resignation adds to a wider pattern of personnel changes across federal health agencies during Trump’s second term, as the administration continues reshaping leadership within the Department of Health and Human Services and revisiting regulatory priorities across multiple divisions.
Officials have signaled an interest in tightening oversight of drug approvals while also accelerating review timelines for certain categories of medical products.
Supporters of Makary have pointed to his willingness to challenge long-standing regulatory practices as evidence of reform efforts inside the agency, while critics argue the FDA struggled to maintain consistency and direction during his tenure.
The competing pressures reflected broader divisions in national health policy debates that have intensified since the pandemic.
FDA Deputy Commissioner for Food Kyle Diamantas is expected to serve as acting commissioner while the White House weighs a permanent replacement to lead the agency through its next phase of policy implementation.
Trump emphasized the importance of the position, noting its significance within the administration’s broader health agenda. “Everybody wants that job. It’s a very important job,” he said.
Makary had been scheduled to testify before a Senate Appropriations subcommittee this week on FDA budget matters prior to his resignation.
Lawmakers had been expected to question agency priorities, including drug approval timelines and regulatory consistency, during the hearing.
His departure follows a tenure marked by regulatory disputes, internal disagreements over policy direction, and broader uncertainty over how the FDA should balance speed, oversight, and political pressure in shaping public health decisions moving forward.
WATCH:
